Overview

A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Primary Gastric Cancer and Colorectal Cancer (CRC)

Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This is a first-in-human, Phase 1 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of exoASO-STAT6 (CDK-004) in patients with advanced Hepatocellular Carcinoma (HCC) and patients with liver metastases from primary gastric cancer and colorectal cancer (CRC).
Phase:
Phase 1
Details
Lead Sponsor:
Codiak BioSciences